Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis.
Identifieur interne : 001166 ( Ncbi/Merge ); précédent : 001165; suivant : 001167Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis.
Auteurs : Stephen A. Bustin [Royaume-Uni] ; Reinhold MuellerSource :
- Clinical science (London, England : 1979) [ 0143-5221 ] ; 2005.
Descripteurs français
- KwdFr :
- MESH :
- biosynthèse : ADN complémentaire.
- diagnostic : Maladies virales, Tumeurs.
- isolement et purification : Retroviridae, Virus à ARN.
- normes : RT-PCR.
- Contrôle de qualité, Humains, Marqueurs génétiques, RT-PCR.
English descriptors
- KwdEn :
- DNA, Complementary (biosynthesis), Genetic Markers, Humans, Neoplasms (diagnosis), Quality Control, RNA Viruses (isolation & purification), Retroviridae (isolation & purification), Reverse Transcriptase Polymerase Chain Reaction (methods), Reverse Transcriptase Polymerase Chain Reaction (standards), Virus Diseases (diagnosis).
- MESH :
- chemical , biosynthesis : DNA, Complementary.
- chemical : Genetic Markers.
- diagnosis : Neoplasms, Virus Diseases.
- isolation & purification : RNA Viruses, Retroviridae.
- methods : Reverse Transcriptase Polymerase Chain Reaction.
- standards : Reverse Transcriptase Polymerase Chain Reaction.
- Humans, Quality Control.
Abstract
qRT-PCR (real-time reverse transcription-PCR) has become the benchmark for the detection and quantification of RNA targets and is being utilized increasingly in novel clinical diagnostic assays. Quantitative results obtained by this technology are not only more informative than qualitative data, but simplify assay standardization and quality management. qRT-PCR assays are most established for the detection of viral load and therapy monitoring, and the development of SARS (severe acute respiratory syndrome)-associated coronavirus qRT-PCR assays provide a textbook example of the value of this technology for clinical diagnostics. The widespread use of qRT-PCR assays for diagnosis and the detection of disease-specific prognostic markers in leukaemia patients provide further examples of their usefulness. Their value for the detection of disease-associated mRNA expressed by circulating tumour cells in patients with solid malignancies is far less apparent, and the clinical significance of results obtained from such tests remains unclear. This is because of conceptual reservations as well as technical limitations that can interfere with the diagnostic specificity of qRT-PCR assays. Therefore, although it is evident that qRT-PCR assay has become a useful and important technology in the clinical diagnostic laboratory, it must be used appropriately and it is essential to be aware of its limitations if it is to fulfil its potential.
DOI: 10.1042/CS20050086
PubMed: 16171460
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002537
- to stream PubMed, to step Curation: 002537
- to stream PubMed, to step Checkpoint: 002546
Links to Exploration step
pubmed:16171460Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis.</title><author><name sortKey="Bustin, Stephen A" sort="Bustin, Stephen A" uniqKey="Bustin S" first="Stephen A" last="Bustin">Stephen A. Bustin</name><affiliation wicri:level="4"><nlm:affiliation>Centre for Academic Surgery, Institute of Cell and Molecular Science, Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London, London E1 1BB, U.K. s.a.bustin@qmul.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Academic Surgery, Institute of Cell and Molecular Science, Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London, London E1 1BB</wicri:regionArea><orgName type="university">Université de Londres</orgName><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Mueller, Reinhold" sort="Mueller, Reinhold" uniqKey="Mueller R" first="Reinhold" last="Mueller">Reinhold Mueller</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16171460</idno><idno type="pmid">16171460</idno><idno type="doi">10.1042/CS20050086</idno><idno type="wicri:Area/PubMed/Corpus">002537</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002537</idno><idno type="wicri:Area/PubMed/Curation">002537</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002537</idno><idno type="wicri:Area/PubMed/Checkpoint">002546</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002546</idno><idno type="wicri:Area/Ncbi/Merge">001166</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis.</title><author><name sortKey="Bustin, Stephen A" sort="Bustin, Stephen A" uniqKey="Bustin S" first="Stephen A" last="Bustin">Stephen A. Bustin</name><affiliation wicri:level="4"><nlm:affiliation>Centre for Academic Surgery, Institute of Cell and Molecular Science, Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London, London E1 1BB, U.K. s.a.bustin@qmul.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Academic Surgery, Institute of Cell and Molecular Science, Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London, London E1 1BB</wicri:regionArea><orgName type="university">Université de Londres</orgName><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Mueller, Reinhold" sort="Mueller, Reinhold" uniqKey="Mueller R" first="Reinhold" last="Mueller">Reinhold Mueller</name></author></analytic><series><title level="j">Clinical science (London, England : 1979)</title><idno type="ISSN">0143-5221</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>DNA, Complementary (biosynthesis)</term><term>Genetic Markers</term><term>Humans</term><term>Neoplasms (diagnosis)</term><term>Quality Control</term><term>RNA Viruses (isolation & purification)</term><term>Retroviridae (isolation & purification)</term><term>Reverse Transcriptase Polymerase Chain Reaction (methods)</term><term>Reverse Transcriptase Polymerase Chain Reaction (standards)</term><term>Virus Diseases (diagnosis)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN complémentaire (biosynthèse)</term><term>Contrôle de qualité</term><term>Humains</term><term>Maladies virales (diagnostic)</term><term>Marqueurs génétiques</term><term>RT-PCR ()</term><term>RT-PCR (normes)</term><term>Retroviridae (isolement et purification)</term><term>Tumeurs (diagnostic)</term><term>Virus à ARN (isolement et purification)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>DNA, Complementary</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Genetic Markers</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>ADN complémentaire</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Neoplasms</term><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Maladies virales</term><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>RNA Viruses</term><term>Retroviridae</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Retroviridae</term><term>Virus à ARN</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Reverse Transcriptase Polymerase Chain Reaction</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>RT-PCR</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Reverse Transcriptase Polymerase Chain Reaction</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Quality Control</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Contrôle de qualité</term><term>Humains</term><term>Marqueurs génétiques</term><term>RT-PCR</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">qRT-PCR (real-time reverse transcription-PCR) has become the benchmark for the detection and quantification of RNA targets and is being utilized increasingly in novel clinical diagnostic assays. Quantitative results obtained by this technology are not only more informative than qualitative data, but simplify assay standardization and quality management. qRT-PCR assays are most established for the detection of viral load and therapy monitoring, and the development of SARS (severe acute respiratory syndrome)-associated coronavirus qRT-PCR assays provide a textbook example of the value of this technology for clinical diagnostics. The widespread use of qRT-PCR assays for diagnosis and the detection of disease-specific prognostic markers in leukaemia patients provide further examples of their usefulness. Their value for the detection of disease-associated mRNA expressed by circulating tumour cells in patients with solid malignancies is far less apparent, and the clinical significance of results obtained from such tests remains unclear. This is because of conceptual reservations as well as technical limitations that can interfere with the diagnostic specificity of qRT-PCR assays. Therefore, although it is evident that qRT-PCR assay has become a useful and important technology in the clinical diagnostic laboratory, it must be used appropriately and it is essential to be aware of its limitations if it is to fulfil its potential.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16171460</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0143-5221</ISSN><JournalIssue CitedMedium="Print"><Volume>109</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Clinical science (London, England : 1979)</Title><ISOAbbreviation>Clin. Sci.</ISOAbbreviation></Journal><ArticleTitle>Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis.</ArticleTitle><Pagination><MedlinePgn>365-79</MedlinePgn></Pagination><Abstract><AbstractText>qRT-PCR (real-time reverse transcription-PCR) has become the benchmark for the detection and quantification of RNA targets and is being utilized increasingly in novel clinical diagnostic assays. Quantitative results obtained by this technology are not only more informative than qualitative data, but simplify assay standardization and quality management. qRT-PCR assays are most established for the detection of viral load and therapy monitoring, and the development of SARS (severe acute respiratory syndrome)-associated coronavirus qRT-PCR assays provide a textbook example of the value of this technology for clinical diagnostics. The widespread use of qRT-PCR assays for diagnosis and the detection of disease-specific prognostic markers in leukaemia patients provide further examples of their usefulness. Their value for the detection of disease-associated mRNA expressed by circulating tumour cells in patients with solid malignancies is far less apparent, and the clinical significance of results obtained from such tests remains unclear. This is because of conceptual reservations as well as technical limitations that can interfere with the diagnostic specificity of qRT-PCR assays. Therefore, although it is evident that qRT-PCR assay has become a useful and important technology in the clinical diagnostic laboratory, it must be used appropriately and it is essential to be aware of its limitations if it is to fulfil its potential.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bustin</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Centre for Academic Surgery, Institute of Cell and Molecular Science, Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London, London E1 1BB, U.K. s.a.bustin@qmul.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>Reinhold</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Sci (Lond)</MedlineTA><NlmUniqueID>7905731</NlmUniqueID><ISSNLinking>0143-5221</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018076">DNA, Complementary</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018076" MajorTopicYN="N">DNA, Complementary</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011786" MajorTopicYN="N">Quality Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012328" MajorTopicYN="N">RNA Viruses</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012190" MajorTopicYN="N">Retroviridae</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>165</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16171460</ArticleId><ArticleId IdType="pii">CS20050086</ArticleId><ArticleId IdType="doi">10.1042/CS20050086</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement><orgName><li>Université de Londres</li></orgName></list><tree><noCountry><name sortKey="Mueller, Reinhold" sort="Mueller, Reinhold" uniqKey="Mueller R" first="Reinhold" last="Mueller">Reinhold Mueller</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Bustin, Stephen A" sort="Bustin, Stephen A" uniqKey="Bustin S" first="Stephen A" last="Bustin">Stephen A. Bustin</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001166 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001166 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:16171460
|texte= Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:16171460" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |